Fangping Wan

Fangping Wan

Auto-generated profile, based on publicly available information

Fangping Wan

Machine Biology Group, Departments of Psychiatry and Microbiology, Institute for Biomedical Informatics, Institute for Translational Medicine and Therapeutics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, USA

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 March 2022 in Digital Discovery
Verified
Journal Article
Open access
PDF file
FWFangping Wan
Fangping Wan
DKDaphne Kontogiorgos-Heintz
Daphne Kontogiorgos-Heintz
Cesar de la FuenteCesar de la Fuente
Cesar de la Fuente
Computers can already be programmed for superhuman pattern recognition of images and text. For machines to discover novel molecules, they must first be trained to sort through the many characteristics of molecules and determine which properties should be retained, suppressed, or enhanced to optimize functions of interest. Machines need to be able to understand, read, write, and eventually create new molecules. Today, this creative process relies on deep generative models, which have gained popularity since powerful deep neural networks were introduced to generative model frameworks. In recent years, they have demonstrated excellent ability to model complex distribution of real-word data (e.g., images, audio, text, molecules, and biological sequences). Deep generative models can generate data beyond those provided in training samples, thus yielding an efficient and rapid tool for exploring the massive search space of high-dimensional data such as DNA/protein sequences and facilitating the design of biomolecules with desired functions. Here, we review the emerging field of deep generative models applied to peptide science. In particular, we discuss several popular deep generative model frameworks as well as their applications to generate peptides with various kinds of properties (e.g., antimicrobial, anticancer, cell penetration, etc). We conclude our review with a discussion of current limitations and future perspectives in this emerging field.

1 October 2019 in Genomics, Proteomics & Bioinformatics
Verified
Journal Article
Open access
FWFangping Wan
Fangping Wan
YZYue Zhu
Yue Zhu
HHHailin Hu
Hailin Hu
ADAntao Dai
Antao Dai
XCXiaoqing Cai
Xiaoqing Cai
JZJianyang Zeng
Jianyang Zeng
Accurate identification of compound–protein interactions (CPIs) in silico may deepen our understanding of the underlying mechanisms of drug action and thus remarkably facilitate drug discovery and development. Conventional similarity- or docking-based computational methods for predicting CPIs rarely exploit latent features from currently available large-scale unlabeled compound and protein data and often limit their usage to relatively small-scale datasets. In the present study, we propose DeepCPI, a novel general and scalable computational framework that combines effective feature embedding (a technique of representation learning) with powerful deep learning methods to accurately predict CPIs at a large scale. DeepCPI automatically learns the implicit yet expressive low-dimensional features of compounds and proteins from a massive amount of unlabeled data. Evaluations of the measured CPIs in large-scale databases, such as ChEMBL and BindingDB, as well as of the known drug–target interactions from DrugBank, demonstrated the superior predictive performance of DeepCPI. Furthermore, several interactions among small-molecule compounds and three G protein-coupled receptor targets (glucagon-like peptide-1 receptor, glucagon receptor, and vasoactive intestinal peptide receptor) predicted using DeepCPI were experimentally validated. The present study suggests that DeepCPI is a useful and powerful tool for drug discovery and repositioning. The source code of DeepCPI can be downloaded from https://github.com/FangpingWan/DeepCPI.

3 June 2021 in Nature Communications
Verified
Journal Article
Open access
PDF file
ACAnna Cichońska
Anna Cichońska
BRBalaguru Ravikumar
Balaguru Ravikumar
RARobert Allaway
Robert Allaway
FWFangping Wan
Fangping Wan
SPSungjoon Park
Sungjoon Park
TATero Aittokallio
Tero Aittokallio
Despite decades of intensive search for compounds that modulate the activity of particular protein targets, a large proportion of the human kinome remains as yet undrugged. Effective approaches are therefore required to map the massive space of unexplored compound–kinase interactions for novel and potent activities. Here, we carry out a crowdsourced benchmarking of predictive algorithms for kinase inhibitor potencies across multiple kinase families tested on unpublished bioactivity data. We find the top-performing predictions are based on various models, including kernel learning, gradient boosting and deep learning, and their ensemble leads to a predictive accuracy exceeding that of single-dose kinase activity assays. We design experiments based on the model predictions and identify unexpected activities even for under-studied kinases, thereby accelerating experimental mapping efforts. The open-source prediction algorithms together with the bioactivities between 95 compounds and 295 kinases provide a resource for benchmarking prediction algorithms and for extending the druggable kinome.

18 January 2022 in Cell Reports Medicine
Verified
Journal Article
Open access
EDEugene F. Douglass
Eugene F. Douglass
RARobert Allaway
Robert Allaway
BSBence Szalai
Bence Szalai
WWWenyu Wang
Wenyu Wang
TTTingzhong Tian
Tingzhong Tian
ACAndrea Califano
Andrea Califano
The Columbia Cancer Target Discovery and Development (CTD2) Center is developing PANACEA, a resource comprising dose-responses and RNA sequencing (RNA-seq) profiles of 25 cell lines perturbed with ∼400 clinical oncology drugs, to study a tumor-specific drug mechanism of action. Here, this resource serves as the basis for a DREAM Challenge assessing the accuracy and sensitivity of computational algorithms for de novo drug polypharmacology predictions. Dose-response and perturbational profiles for 32 kinase inhibitors are provided to 21 teams who are blind to the identity of the compounds. The teams are asked to predict high-affinity binding targets of each compound among ∼1,300 targets cataloged in DrugBank. The best performing methods leverage gene expression profile similarity analysis as well as deep-learning methodologies trained on individual datasets. This study lays the foundation for future integrative analyses of pharmacogenomic data, reconciliation of polypharmacology effects in different tumor contexts, and insights into network-based assessments of drug mechanisms of action.

13 May 2026 in Nature Machine Intelligence
Verified
Journal Article
Open access
PDF file
MTMarcelo D. T. Torres
Marcelo D. T. Torres
YZYimeng Zeng
Yimeng Zeng
FWFangping Wan
Fangping Wan
NMNatalie Maus
Natalie Maus
JGJacob Gardner
Jacob Gardner
Cesar de la FuenteCesar de la Fuente
Cesar de la Fuente
Antibiotic resistance is rising globally, demanding faster, more reliable routes to design antimicrobial candidates. Although artificial-intelligence-based methods have accelerated antimicrobial discovery, most are designed to screen fixed libraries or generate candidates broadly, rather than optimize existing peptide scaffolds under practical design constraints. Here, to address this challenge, we present APEX generative optimization (ApexGO). ApexGO uses a transformer variational autoencoder that embeds peptide sequences in a continuous latent space, whereas Bayesian optimization efficiently proposes sequence edits to boost antimicrobial potency. Unlike traditional approaches, ApexGO generates peptide sequences through modifications of template peptides, opening avenues for peptide design and antibiotic discovery. Using ten peptides as templates, ApexGO generated optimized derivatives with enhanced antimicrobial properties. We chemically synthesized 100 of these compounds and conducted comprehensive in vitro characterizations, including assessments of antimicrobial activity, mechanism of action, secondary structure and cytotoxicity. In particular, ApexGO achieved an 85% ground-truth experimental hit rate and a 72% success rate in enhancing antimicrobial activity against Gram-negative pathogens, outperforming previously reported methods for antibiotic discovery and optimization. In two preclinical mouse models of Acinetobacter baumannii infection, artificial-intelligence-optimized molecules exhibited potent anti-infective activity superior to their template controls and comparable with or exceeding that of last-resort antibiotic. These findings highlight the potential of ApexGO as a generative artificial intelligence approach for peptide design and antibiotic optimization, offering a powerful tool to accelerate antibiotic discovery.

9 February 2021 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
PFPeiyuan Feng
Peiyuan Feng
AXAn Xiao
An Xiao
MFMeng Fang
Meng Fang
FWFangping Wan
Fangping Wan
SLShuya Li
Shuya Li
JZJianyang Zeng
Jianyang Zeng
Significance: Although plenty of studies have identified the RNA polymerase II (Pol II) pausing events in eukaryotes and demonstrated the regulatory roles of such events in gene expression and RNA processing, there was no study that systematically modeled the global landscape of Pol II pausing in the whole genome. Here, we have developed a deep learning framework that can accurately predict the Pol II pausing events from the contextual DNA sequences. Through applying our powerful computational approach to predict the pausing tendencies on interested regions in the human genome, we provided useful insights into understanding the relations between Pol II pausing events and alternative splicing, transcription factors, histone modifications, and DNA methylation.